JULIAN L AMBRUS
Medical Practice in Buffalo, NY

6528057, Mar 4, 2003

Aug 30, 1999

09/385166

Julian L. Ambrus - Buffalo NY 14222-1509
David O. Scamurra - Eggertsville NY 14226

A61K 3900

4241401, 210645, 210646, 435 4, 435 6, 435 71, 436501, 5303881, 5303891, 5303894, 604 401, 604 501, 604 502

This invention discloses a method for reducing the viral load by removal of viruses or fragments or components thereof from the blood by extracorporeally circulating blood through hollow fibers which have in the porous exterior surface, immobilized affinity molecules having specificity for viral components. Passage of the fluid through the hollow fibers causes the viral particles to bind to the affinity molecules thereby reducing the viral load in the effluent.

2006012, Jun 8, 2006

Nov 22, 2005

11/284693

Jui Wang - Williamsville NY, US
Long Shen - Tonawanda NY, US
Chongjie Zhang - Chengdu, CN
Julian Ambrus - Buffalo NY, US

A61K 48/00

514044000

The present invention provides antisense oligoribonucleotides with sequences that recognize and bind to the c-myc gene or c-myc mRNA, where one or more sugar residues of the oligoribonucleotides are modified by the substitution of DNP at the 2′-O position. The antisense oligoribonucleotides can be used for inhibiting the growth of cells in which the c-myc gene is overexpressed by down-regulation of transcription of c-myc RNA or translation of the c-myc protein. The antisense oligoribonucleotides can also be used for diagnostic purposes to identify the overexpression of the c-myc gene. The nucleotide sequence of the DNP-oligoribonucleotides is complementary to the sequence 578 to 598 in c-myc mRNA and does not contain a G-quartet motif. This DNP-RNA can silence c-myc gene expression both in vitro and in vivo with high efficacy and sequence specificity.

2013004, Feb 14, 2013

Jan 21, 2011

13/574265

Julian L. Ambrus - Buffalo NY, US
Long Shen - Williamsville NY, US

G01N 33/566, C07K 14/47, C07K 17/00, C12N 9/88

435 792, 435232, 436501, 435 71, 530350, 530402

Provided are methods and compositions for determining whether an individual has Sjögren's disease (SD). The method entails determining in a biological sample from the individual the presence of antibodies directed to salivary gland protein 1 (SP-I), parotid secretory protein (PSP), carbonic anhydrase 6 (C A6), or determining a combination of the antibodies. Determining that the individual has SD is based on the presence of the antibodies. The method provides for detection of early SD. Kits for antibody detection containing the antigens to which the antibodies of SD patients are directed are also provided.

2008014, Jun 19, 2008

Oct 26, 2007

11/977778

Julian L. Ambrus - Buffalo NY, US
Long Shen - Tonawanda NY, US
Richard Ford - Houston TX, US
Chongjie Zhang - Chengdu, CN

A61K 31/70, C07H 21/00, A61P 43/00, C07K 16/18

514 44, 536 231, 5303879, 5303917

Provided are antisense poly-2′-O-(2,4-dinitrophenyl)oligoribonucleotides which are complementary to the IL-14α gene and/or transcribed IL-14α mRNA. Also provided are monoclonal antibodies reactive with discreet IL-14α peptides. The oligoribonucleotides and monoclonal antibodies are useful in inhibiting the growth of lymphocytes.